Bing Z Carter
Bing Z Carter
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,✉,
Po Yee Mak
Po Yee Mak
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Wenjing Tao
Wenjing Tao
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Edward Ayoub
Edward Ayoub
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Lauren B Ostermann
Lauren B Ostermann
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Xuelin Huang
Xuelin Huang
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX USA
2,
Sanam Loghavi
Sanam Loghavi
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
3,
Steffen Boettcher
Steffen Boettcher
4Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
4,
Yuki Nishida
Yuki Nishida
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Vivian Ruvolo
Vivian Ruvolo
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Paul E Hughes
Paul E Hughes
5Oncology Research, Amgen Inc, Thousand Oaks, CA USA
5,
Phuong K Morrow
Phuong K Morrow
6Amgen Inc, Thousand Oaks, CA USA
6,
Torsten Haferlach
Torsten Haferlach
7MLL Munich Leukemia Laboratory, Munich, Germany
7,
Steven Kornblau
Steven Kornblau
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Muharrem Muftuoglu
Muharrem Muftuoglu
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,
Michael Andreeff
Michael Andreeff
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
1,✉
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX USA
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
4Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
5Oncology Research, Amgen Inc, Thousand Oaks, CA USA
6Amgen Inc, Thousand Oaks, CA USA
7MLL Munich Leukemia Laboratory, Munich, Germany
Collection date 2023 Dec.
Subject terms: Cancer, Leukaemia
© The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
PDF (381.2 KB)
